LAB Q1 2025: Instrument orders surge 24% y/y on strong demand
- Growing Instrument Demand: Analysts noted strong traction in instrument sales—particularly for the Hyperion XTi—with a growing sales funnel that isn't driven by pull-forward pressures, suggesting sustainable future revenue growth.
- Innovative Product Pipeline & Partnerships: The launch of new products like the single SOMAmer reagents and progress with the Illumina partnership signal potential long-term expansion in new market segments despite initial modest contributions.
- Resilient Biopharma Segment: Despite broader academic funding challenges, management highlighted healthy growth and a strong funnel in the biopharma segment, indicating robust demand from pharmaceutical customers that could drive future earnings.
- U.S. academic uncertainty: Guidance pointed to a mid-teens decline in U.S. academic revenue with delays in consumables and instrument orders due to funding constraints and travel restrictions, potentially further pressuring revenue in upcoming quarters.
- Modest short-term impact from the Illumina partnership: Executives cautioned that while the Illumina collaboration is promising long term, its 2025 revenue contribution will be moderate, which may not sufficiently counterbalance current market headwinds.
- M&A and customer concentration risks: The company's reliance on a few large customers for lab services leads to notable quarter-to-quarter variability, and executing multiple acquisitions in a volatile market could strain resources and delay integration benefits.
| Metric | YoY Change | Reason |
|---|---|---|
Total Revenue | -10% (from $45,540K in Q1 2024 to $40,795K in Q1 2025) | Total Revenue declined by about 10% largely due to lower sales in consumables and lab services, despite some offset from higher instrument sales; this contrasts with the higher revenue in the previous period. |
Net Loss | -19% improvement (from $(32,157)K in Q1 2024 to $(26,033)K in Q1 2025) | Net Loss improved by approximately 19%, driven by significant reductions in operating expenses, especially the dramatic cut in transaction & integration expenses and other cost-saving measures, which offset revenue declines observed in the previous period. |
Gross Profit | -18% (from $24,188K in Q1 2024 to $19,741K in Q1 2025) | Gross Profit decreased by roughly 18% as a reflection of the lower sales volume and shifting product mix from the prior period, where higher consumables and lab services revenue had supported stronger gross profit margins. |
Transaction & Integration Expenses |
| A dramatic one-time expense incurred in Q1 2024, associated with merger and integration activities, was largely absent in Q1 2025, resulting in transaction & integration expenses falling by over 90% compared to the previous period. |
Operating Cash Flow | 51% improvement (from $(62,476)K in Q1 2024 to $(30,283)K in Q1 2025) | Operating Cash Flow improved by around 51%, primarily due to lower operating expenses, absence of financing activities like stock repurchases, and fewer one-off charges in Q1 2025 compared to the higher cash outflows from operations in the previous period. |
Cash & Cash Equivalents | -9.6% (from $166,728K in Q4 2024 to $150,880K in Q1 2025) | Cash & Cash Equivalents decreased moderately by about 9.6%, likely reflecting the usage of cash for operations or strategic investments during Q1 2025, which contrasts with the higher cash position at the end of the prior period. |
Total Assets | -5.3% (from $612,344K in Q4 2024 to $579,597K in Q1 2025) | Total Assets declined by roughly 5.3% due to decreases in cash and short-term investments, which outweighed minor increases in accounts receivable and inventory compared to the previous period. |
Accounts Receivable | +5.6% (from $33,608K in Q4 2024 to $35,480K in Q1 2025) | Accounts Receivable increased by approximately 5.6%, suggesting either increased credit sales or slower collections compared to Q4 2024, reflecting a potential shift in customer payment behavior or sales patterns from the prior period. |
| Metric | Period | Previous Guidance | Current Guidance | Change |
|---|---|---|---|---|
Revenue Guidance | FY 2025 | $165 million to $175 million | $165 million to $175 million | no change |
Americas Academic Revenue Decline | FY 2025 | Mid‐teens percentage decline with a high single-digit million-dollar impact | Mid‐teens percentage decline with a high single-digit million-dollar impact | no change |
Tariff Impact | FY 2025 | Low single-digit million-dollar impact to gross margin and adjusted EBITDA | Low single-digit millions of dollars | no change |
Adjusted EBITDA | FY 2025 | Target: Adjusted EBITDA breakeven in 2026 | Target: Adjusted EBITDA positive by FY 2026 | raised |
Back Half Weighted Revenue | FY 2025 | no prior guidance | Expected to be back half weighted | no prior guidance |
| Topic | Previous Mentions | Current Period | Trend |
|---|---|---|---|
Instrument Sales Demand & Sales Funnel Dynamics | Q3 2024: Reported significant year‐over‐year declines (e.g. 42% drop) with a focus on building the funnel ( ). Q4 2024: Noted sequential improvements and emerging signs of recovery despite earlier declines. | Q1 2025: CEO expressed cautious optimism with strong sales funnel momentum and encouraging growth in key instruments like the Hyperion XTi ( ). | Shift from steep declines and caution to a more optimistic, yet measured, outlook as the sales funnel improves amid challenging conditions. |
Illumina Partnership & New Product Launches | Q2–Q4 2024: Consistently discussed the strategic partnership with Illumina, new product launches (e.g. individual SOMAmer reagents, integration with SomaScan) and timing uncertainties; emphasized a long-term revenue play ( , , ). | Q1 2025: Continued emphasis on the strategic importance of the Illumina collaboration with moderated short-term revenue expectations, while highlighting long-term value and product expansion ( , ). | Ongoing focus with maintained optimism; sentiment remains positive over the long term but with a cautious view on immediate revenue impact. |
Innovative Product Pipeline & Growth Initiatives | Q2–Q4 2024: Detailed discussion around launching individual SOMAmer reagents, Omics as a Service offerings, and spatial proteomics; initiatives aimed at diversification and high‐precision technology advancement ( , , ). | Q1 2025: Reiterated progress with official launches (e.g. SOMAmer reagents), strong clinical applications for the SomaScan platform and increasing instrument placements (e.g. Hyperion XTi), reinforcing growth in lab services ( , , ). | Enhanced and broadening focus: product diversification and new technology initiatives are increasingly seen as long‐term growth drivers. |
Biopharma Segment Strength & Pharma Customer Concentration Risks | Q3–Q4 2024: Noted historical reliance on a few large customers causing revenue volatility, though steps were being taken to diversify; lab services impacted by concentration risks ( , , ). Q2 2024: Also mentioned risks linked to dependence on large pharma accounts ( , ). | Q1 2025: Emphasized robust biopharma engagement with clear signs of new customer wins and reduced concentration, even as historical dependence still produces some variability ( ). | Improving strength as diversification efforts begin to reduce historical concentration risks, thereby enhancing long-term stability. |
Academic Revenue Challenges & NIH Funding Reductions | Q4 2024: Highlighted concerns around funding delays and anticipated mid-teens percentage decline in Americas academic revenue; this topic was not mentioned in Q3 or Q2 2024 ( , ). | Q1 2025: Continued focus on academic revenue challenges with forecasts of significant declines and ongoing NIH funding delays impacting instrument and consumables orders ( , ). | Emerging as a consistent concern in recent periods with clear recognition of funding challenges that could impact future academic business. |
Cost Synergies, Expense Reduction & Path to EBITDA Breakeven | Q2–Q4 2024: Emphasized progress with operationalizing $80M in synergies, significant reductions in non‐GAAP operating expenses and improvement in EBITDA metrics across quarters ( , , , ). | Q1 2025: Reported an additional $10M in cost reductions on top of previous savings, with further improvements in operating expense metrics and a stronger outlook toward adjusted EBITDA breakeven in 2026 ( , ). | Continued positive progress with accelerated cost reductions and operational improvements reinforcing the path to profitability. |
Strategic M&A Activity & Risks from Customer Concentration | Q2–Q4 2024: Discussed M&A as a strategic lever to consolidate the fragmented life sciences sector while revealing risks from high customer concentration (e.g. $15–$20M headwind from top accounts) that cause revenue timing volatility ( , , , ). | Q1 2025: Reaffirmed commitment to strategic acquisitions with a healthy cash position alongside ongoing efforts to diversify the customer base and mitigate concentration risks ( , ). | Steady focus: M&A remains a core strategy to drive growth while diversification efforts help to alleviate customer concentration risks. |
Global Market Dynamics (China rebound & international sales challenges) | Q3 2024: Reported weak instrument sales in China with hopes for a rebound as stimulus dollars flow, alongside challenges in other regions like Japan, Korea, and parts of Europe ( , ). Q4 2024: Addressed tariff impacts and U.S.-China trade dynamics adding complexity to international sales ( ). | Q1 2025: Emphasized resilience in international markets with cautious optimism regarding China’s rebound potential while continuing to monitor tariff-driven challenges across global trade ( , ). | Mixed sentiment: Global challenges persist with tariffs and trade complexities, yet there is cautious optimism for recovery in key markets like China. |
Management Stability & Execution Risks | Q2 2024: Noted CFO Jeffrey Black’s departure, with details on transition plans and associated execution concerns; Q3 2024: Mentioned interim CFO Alex Kim’s strong credentials, and Q4 2024: No new concerns were raised ( , , , ). | Q1 2025: No mention of management or execution stability issues, indicating that earlier CFO transition risks have been effectively addressed. | Improved stability: Earlier concerns over CFO departure and execution risks have been resolved through seamless leadership transitions and strong internal management. |
-
M&A Focus
Q: M&A pipeline update?
A: Management remains disciplined, targeting 4–6 acquisitions over the next 18 months as part of their consolidation strategy, supported by a strong cash position. -
Cost & EBITDA
Q: Is EBITDA improving post-cost actions?
A: The firm’s additional $10 million cost reduction in January boosted operating discipline, contributing to a 29% improvement in adjusted EBITDA loss. -
Instrument Demand
Q: Any pull-forward in instrument orders?
A: Instrument demand is robust—up 24% year-over-year—with no significant pull-forward impact from tariffs, reflecting a strong sales funnel. -
Academic Trends
Q: How are U.S. academic orders trending?
A: U.S. academic revenue continues a mid-teens decline due to funding constraints and order delays, particularly affecting consumables. -
Illumina Partnership
Q: Illumina revenue impact in 2025?
A: The partnership with Illumina is expected to yield moderate revenue growth in 2025, with substantial upside anticipated in 2026 and beyond. -
Biopharma Trends
Q: What’s the outlook for biopharma spending?
A: There is healthy growth among biopharma customers, with increased activity and a broader engagement beyond a few large accounts, despite some quarterly variability. -
SOMAmer Reagents
Q: How’s the single reagent feedback?
A: Early feedback on the single SOMAmer reagents is positive; it complements their 11,000-reagent portfolio, though high short-term volumes aren’t expected. -
Revenue Weighting
Q: What is the period revenue split?
A: While specifics are not disclosed, internal funnel metrics indicate a back-half weighted revenue pattern driven by larger projects later in the year.
Research analysts covering STANDARD BIOTOOLS.